IP Library Granted Patent US 7,851,212
Granted Patent B2
US 7,851,212 · App. 10/275,993 · Granted Dec 14, 2010

Immunogenic polypeptides encoded by MAGE minigenes and uses thereof

Assignees: Sanofi Pasteur Limited; Ludwig Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,851,212
App. No.
10/275,993
Granted
Dec 14, 2010
Kind
B2
Abstract

The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.

Claims (20)

1. An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 2-34 of SEQ ID NO.: 1) and the amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6).

2. An isolated nucleic acid molecule encoding a polypeptide comprising a first amino acid sequence Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 2-34 of SEQ ID NO.: 1), and a second amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6), wherein the first and second amino acid sequences are separated by a protease cleavage site.

3. An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 2-34 of SEQ ID NO.: 1), the amino acid sequence Asn Lys Arg Lys (amino acid residues 35-38 of SEQ ID NO.: 1), and the amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6).

4. An isolated nucleic acid molecule encoding a polypeptide comprising a first amino acid sequence Met Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 1-34 of SEQ ID NO.: 1) and a second amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6), wherein the first and second amino acid sequences are separated by a protease cleavage site.

5. An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence Met Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 1-34 of SEQ ID NO.: 1), the amino acid sequence Asn Lys Arg Lys (amino acid residues 35-38 of SEQ ID NO.: 1), and the amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6).

6. An isolated nucleic acid molecule encoding a polypeptide comprising a first amino acid sequence Glu Ala Asp Pro Thr Gly His Ser Tyr (SEQ ID NO.: 5), a second amino acid sequence Asn Lys Arg Lys (amino acid residues 35-38 of SEQ ID NO.: 1), and a third amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.: 6).

7. An isolated nucleic acid molecule comprising SEQ ID NO.: 2.

8. The isolated nucleic acid molecule of SEQ ID NO. 2.

9. A recombinant expression vector comprising a nucleic acid molecule encoding a polypeptide selected from the group consisting of:

(a) a polypeptide comprising the amino acid sequence Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 2-34 of SEQ ID NO.: 1) and the amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6);

(b) a polypeptide comprising a first amino acid sequence Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 2-34 of SEQ ID NO.: 1) and a second amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6), wherein the first and second amino acid sequences are separated by a protease cleavage site;

(c) a polypeptide comprising the amino acid sequence Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 2-34 of SEQ ID NO.: 1), the amino acid sequence Asn Lys Arg Lys (amino acid residues 35-38 of SEQ ID NO.: 1), and the amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6);

(d) a polypeptide comprising a first amino acid sequence Met Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 1-34 of SEQ ID NO.: 1) and a second amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6), wherein the first and second amino acid sequences are separated by a protease cleavage site;

(e) a polypeptide comprising the amino acid sequence Met Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly (amino acid residues 1-34 of SEQ ID NO.: 1), the amino acid sequence Asn Lys Arg Lys (amino acid residues 35-38 of SEQ ID NO.: 1), and the amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.:6); and,

(f) a polypeptide comprising a first amino acid sequence Glu Ala Asp Pro Thr Gly His Ser Tyr (SEQ ID NO.: 5), a second amino acid sequence Asn Lys Arg Lys (amino acid residues 35-38 of SEQ ID NO.: 1), and a third amino acid sequence Glu Val Asp Pro Ile Gly His Leu Tyr (SEQ ID NO.: 6).

10. The recombinant expression vector of claim 9 wherein the expression vector is selected from the group consisting of a cosmid, plasmid, and a viral vector.

11. The recombinant expression vector of claim 10 wherein the viral vector is selected from the group consisting of adenovirus, alphavirus and poxvirus.

12. The recombinant expression vector of claim 11 wherein the poxvirus is ALVAC or ALVAC(2).

13. A composition comprising a recombinant expression vector of claim 9 and a pharmaceutically acceptable vehicle or diluent.

14. The composition of claim 13 further comprising an adjuvant.

Assignments (1)
CHANGE OF NAME Recorded Oct 27, 2010
From: AVENTIS PASTEUR LIMITED
To: SANOFI PASTEUR LIMITED
Reel/Frame 025203/0950 →
Continuity (4)
Provisional Application 6020297000 · May 10, 2000
Provisional Application 6020357800 · May 11, 2000
Provisional Application 6024238800 · Oct 20, 2000
Related Publication 20040033234A1 · Feb 19, 2004